JDD Issue Highlights | December 2021
As 2021 draws to a close, the Journal of Drugs in Dermatology ends the year on a high note! Featuring a strong line up of editorials, original articles, and case reports, the December issue of the JDD includes topics ranging from new treatments for hyperpigmentation, tumescent anesthesia, HS, cosmeceuticals, lower extremity reconstruction, laser hair and identity in transgender men, and everyt …
As 2021 draws to a close, the Journal of Drugs in Dermatology ends the year on a high note! Featuring a strong line up of editorials, original articles, and case reports, the December issue of the JDD includes topics ranging from new treatments for hyperpigmentation, tumescent anesthesia, HS, cosmeceuticals, lower extremity reconstruction, laser hair and identity in transgender men, and everyt … 
The May issue of the Journal of Drugs in Dermatology features dermatology articles on topics ranging from treatment updates on Port-Wine stain to the protective effect that liposomal bovine colostrum exerts on skin aging using telomere length as an aging biomarker. Straight from the JDD Editor’s desk, we share this month’s issue highlights:
Authors analyze extrusion forces of various produ … 
The following two cases presented by JDD authors Ryan A. Gall MD, John D. Peters MD, and Alyson J. Brinker MD add to the growing literature supporting the use of dupilumab in the treatment of patients with recalcitrant dyshidrotic eczema, both with and without diagnosed contact allergens.
Introduction
Dyshidrotic eczema, also known as dyshidrosis or pompholyx when involving larger bullae, is a c … 
Atopic dermatitis (AD) is a chronic inflammatory skin disease. The pathogenesis of AD is complex with many mediators involved and can be broken down into 4 categories:
Immune dysregulation
Abnormal skin barrier
Abnormal itch/scratch cycle
Abnormal skin microbiome
In AD, there is a breakdown in molecular control of the immune system, leading to overproduction and expressi … 
Atopic dermatitis (AD) is a common skin condition characterized by pruritus and occurs as a result of factors related to impaired skin barrier and immune response, as well as environmental and infectious agents. Patients with poor control on topical therapy are looking for safe and effective systemic treatments. We continue our series, Therapeutic Cheat Sheet, with a closer look at dupilumab, whic …